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ABSTRACT 
Carrie B. Martin: HH67.2, a promising novel Adeno-Associated Virus (AAV) Vector, shows 
improved muscle specificity and infectivity compared to AAV9  
(Under the direction of Xiao Xiao) 
  
Currently, AAV9 serotype is considered a robust heart and muscle gene delivery vehicle 
widely used in preclinical studies and in a clinical trial for spinal muscle atrophy (SMA). 
However, the systemic delivery of AAV9 with large vector doses leads to undesirable effects 
such as ectopic gene expression in other tissues. These shortcomings may be overcome by using 
certain strategies such as the development of novel AAV vectors with muscle-specific tropism. 
Previously, our lab identified a novel muscle specific AAV vector, HH67, by DNA shuffling and 
in vivo selection.  Similar to other evolved tissue-specific vectors, the HH67 vector showed 
reduced liver tropism, but its transduction efficiency in heart and muscle tissues was still lower 
than that of AAV9. We set out to introduce site-directed mutations of tyrosine (Y) to 
phenylalanine (F) on the surface of AAV capsids which has been shown to significantly increase 
gene transfer efficiency for certain AAV serotypes. In this study, we investigated whether two 
capsid mutations in HH67, Y445F and Y731F (named HH67.2), would enhance gene delivery to 
the muscle while maintaining low non-specific transgene expression. We found that the HH67.2 
mutant had a significant increase in transgene delivery to the muscle compared to AAV9 after 
systemic delivery in C57BL/6 mice via tail-vein injection. In the muscle, expression of the LacZ 
reporter gene (2.5 x 105 ± 65413 units/µg HH67.2 vs 7.2 x 104 ± 8211 units/µg AAV9; 
p=0.0049) and the DNA genome copy number (4.50 ± 2.07 VG/cell HH67.2 vs 1.15 ± 0.197 
   
VG/cell AAV9; p=0.0118) both increased 3.5-fold compared to AAV9. Furthermore, liver and 
other non-specific organs showed up to an 11-fold decrease in HH67.2 vector copy number (11.8 
± 2.5 VG/cell HH67.2 liver vs 126.8 ± 39.6 VG/cell AAV9 liver; p<0.0001). However, HH67.2 
and AAV9 had no significant difference in gene expression in the heart. LacZ expression results 
were confirmed by vector genome copy number via quantitative PCR and X-Gal staining. 
Finally, we also introduced the same Y-F mutations in three similarly shuffled and in vivo 
selected AAV capsids such as M41, H43 and H48, but the mutations decreased infectivities of all 
these capsids. Our results suggest that HH67.2 is a novel AAV vector with enhanced muscle 
specificity and infectivity compared to AAV9 and could be a promising vehicle to deliver 
therapeutic genes to skeletal muscle or heart.   
 
 
 
 
 
 
 
 
 
 
   
Introduction: 
 Adeno-Associated Virus (AAV) continues to be one of the most efficient in vivo gene 
transfer tools for gene therapy applications because of its lack of pathogenicity, broad tissue 
tropism, and ability to achieve sustained expression of therapeutic genes1,2. AAV vectors have 
been used in preclinical and clinical studies for various genetic diseases, such as hemophilia B, 
cystic fibrosis, age-related macular degeneration, and hereditary muscular dystrophies3. Despite 
early successes, high vector doses are required to reach therapeutic benefits resulting in several 
limitations including: risk of host immune response, non-targeted transgene expression, and 
challenges of sufficient vector production. Additionally, animal models have not been able 
predicted immune responses4. With 12 AAV serotypes and over 100 naturally occurring primate 
AAV variants identified to-date along with recombinant AAV (rAAV), investigators have turned 
to other naturally occurring or artificially modified novel AAV capsids to overcome these 
limitations5. 
The AAV capsids are the major determinant of tropism and transduction efficiency, 
making artificially modified AAV capsids an obvious site for experimentation. The novel 
tyrosine-mutant AAVs, first described by Zhong and colleagues6, was developed based on AAV 
transduction factors. Several considerations exist in evaluating AAV transduction efficiency 
including: receptor binding, cell entry, intracellular trafficking, un-coating, second-stranded 
synthesis, and vector genome stabilization1. It was hypothesized that evasion of intracellular 
trafficking could be achieved by decreased tyrosine phosphorylation, subsequent ubiquitination, 
and ultimately preventing AAV proteasome-mediated degradation. Zhong et al6 showed that 
mutating surface exposed tyrosine residues on AAV2 capsid would lead to impressive increases 
in transduction efficiency both in vivo and in vitro.  
   
 Muscular dystrophies are a class of debilitating, often lethal, genetic diseases. AAV 
vector-mediated gene therapy can restore defective genes and proves to be a promising treatment 
for spinal muscle atrophy (SMA). Currently, AAV9 serotype is a robust heart and muscle gene 
delivery vehicle, yet large vector doses and systemic delivery leads to undesirable effects (i.e. 
ectopic gene expression). The creation of novel muscle specific AAV vectors using certain 
strategies could overcome these undesirable limitations. Previously, our lab identified a novel 
muscle specific AAV vector, HH67, by DNA shuffling and in vivo selection. HH67 proved to be 
similar to other evolved tissue-specific vectors with reduced liver tropism, but its transduction 
efficiency in heart and muscle tissues was still lower than that of AAV97. Given the promising 
results of other tyrosine-mutated AAVs, we set out to identify stealthier capsid candidates by 
introduce site-directed mutations of tyrosine (Y) to phenylalanine (F) on the surface of AAV 
capsids. In this study, we investigated whether two capsid mutations in HH67, Y445F and 
Y731F (named HH67.2), would enhance gene delivery to the muscle while maintaining low non-
specific transgene expression. 
Methods: 
Recombinant AAV vectors 
The original AAV9 packaging plasmid was a gift from J. Wilson laboratory of the 
University of Pennsylvania (Philadelphia, PA)8. The HH67 capsid gene was generated in our lab 
by in vitro DNA shuffling and selected by double in vivo screening, previously described by 
Yang et al7. The mutant HH67.2 AAV packaging plasmid was produced by restriction enzyme 
digestion and ligation. The single tyrosine-to-phenylalanine mutation Y445F was cut out of the 
AAV6-Y445F9 vector using restriction enzymes BsiWI (New England Biolabs Inc., Ipswich, 
MA, Cat No. R0553S) and BspEI (New England Biolabs Inc., Ipswich, MA, Cat No. R0540S), 
   
while BsgI (New England Biolabs Inc., Ipswich, MA, Cat No. R0552S) and AgeI (New England 
Biolabs Inc., Ipswich, MA, Cat No. R0540S) were used with the AAV6-Y731F9 vector. The 
mutant fragments were cloned into the HH67 capsid gene via T4 DNA ligase (Promega, 
Madison, WI, Cat No. M1801) and confirmed by sequencing (Fig. 1). 
The plasmids pAAV-CMV-LacZ (with nuclear localization signal, nls) and pAAV-CB-
LacZnls have been described elsewhere10. Recombinant AAV vectors were generated by the 
triple-plasmid transfection method11. Viral stocks were purified by polyethylene glycol (PEG) 
precipitation followed by double CsCl gradient purification12. After three changes of dialysis in 
virus dialysis buffer (1x phosphate-buffer saline (PBS), 2% mannitol, 6mM MgCl2) at room 
temperature for 6 to 8 hours or at 4ºC overnight, vector genome copy titers were determined by 
DNA dot blot and confirmed by quantitative PCR.  
In vivo gene transfer 
 The HH67.2 capsid gene was used to package CMV-LacZ, or CB-LacZ reporter vectors 
for comparison with AAV9 or HH67 packaged ones. For the adult mouse studies, 1.0 to 1.2 x 
1012 viral genome particles (VG)/mouse designated as high dose was injected intravenously via 
tail vein into 6 to 8 week old C57BL/6J mice (purchased from Jackson Laboratory, Bar Harbor, 
ME) for systemic gene delivery and expression. All animal experiments were approved by the 
Institutional Animal Care and Use Committee.  
Vector genome copy determination 
Total DNA was extracted from collected tissues with the DNeasy Blood & Tissue Kit 
(QIAGEN, Valencia, Spain, Cat #69506). To determine the vector copy numbers in the tissues, 
quantitative PCR was performed with a 7300 real-time PCR system (Applied Biosystems, Foster 
   
City, CA). Taqman assay was used for both endogenous control (glucagon gene) and AAV 
vectors. The mouse glucagon gene as an endogenous control allowed normalization of vector 
copy numbers. The sequences for mouse glucagon primers and probes were as follows: 
Glucagon-real-F (mouse): AAGGGACCTTTACCAGTGATGTG; Glucagon-real-R (mouse): 
ACTTACTCTCGCCTTCCTCGG; Taqman mouse glucagon probe: FAM-
CAGCAAAGGAATTCA-MGB. For the target AAV vectors, primers and probes were designed 
to recognize the common BGH polyA sequence and were as follows: BGH-F: 
AGCCTCGACTGTGCCTTCTA; BGH-R: ATGCGATGCAATTTCCTCAT; BGH probe: 
FAM-TGCCAGCCATCTGTTG. The copy number of delivered vector in a specific tissue per 
diploid cell was calculated as: 
𝑣𝑒𝑐𝑡𝑜𝑟 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟
𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 2. 
LacZ activity assay and X-Gal staining for expression of LacZ  
To assess LacZ activity, collected tissue samples were homogenized using tissue specific 
beads. Then, the Galacto-Light Plus kit’s (Applied Biosystems, Bedford, MA) protocol was 
strictly followed to analyze the samples. The relative units of LacZ activity were normalized by 
total protein concentration, which was assessed with a Pierce BCA protein assay kit (cat. no. 
23227; Pierce Biotechnology, Rockford, IL). X-Gal staining protocol was previously described 
in Qiao et al (2002)13.  
For 5-bromo-4-chloro-3-indolyl-β-d-galactoside (X-Gal) staining, the cryo-thin-sectioned 
slides were air-dried and fixed in X-Gal fixative buffer containing 2% formaldehyde and 0.2% 
glutaraldehyde in PBS. After washing with PBS, the slides were subjected to X-Gal staining 
buffer at 37°C overnight. The X-Gal staining buffer consisted of 0.1 M phosphate buffer (pH 
7.3) supplemented with 2 mM MgCl2, 5 mM potassium ferrocyanide (cat. no. P-9287; Sigma-
   
Aldrich) and 5 mM potassium ferricyanide (cat. no. P-8131; Sigma-Aldrich). Before use, X-Gal 
was added at a final concentration of 1 mg/ml13. 
Statistical analysis 
 Data is presented as means ± standard deviation (SD). Comparison among groups was 
performed by one-way analysis of variance (ANOVA) or 2-tailed t-test using Prism 5 software. 
A p-value of less than 0.05 was considered statistically significant.  
Results: 
 In this study, the mutant HH67.2 AAV packaging plasmid was produced by restriction 
enzyme digestion and ligation using previously generated AAV6-Y445F and AAV6-Y731F9 to 
produce HH67.2 (Fig. 1). The mutations were independently confirmed by DNA sequencing. We 
used the AAV vectors containing β-galactosidase (LacZ) reporter gene to visualize the individual 
cells in tissues and quantitate LacZ activity. The LacZ reporter gene was then driven by two 
different promoters: the ubiquitous cytomegalovirus (CMV) promoter and the chicken β-actin 
(CB) promoter. We found no difference in vector titer generated from HH67 vs the HH67.2 
vectors or the wild type AAV9 control, confirming the tyrosine to phenylalanine did not affect 
vector packaging capacity.  
 
 
 
Figure 1. The phylogenetic origin of HH67.2, which was generated by site-directed 
mutations of tyrosine (Y) to phenylalanine (F) in recombinant AAV Vector HH67. 
  
Y445F Y731F 
   
 We first evaluated the tyrosine-mutant HH67.2 to the original HH67 vector with the 
CMV promoter in order to determine whether HH67.2 would enhance gene delivery to the 
muscle while maintaining low non-specific transgene expression seen previously.  Both AAV 
vectors (HH67-CMV-LacZ and HH67.2-CMV-LacZ) were systemically delivered to 6-to-8 week 
old C57BL/6 adult mice by tail vein injection at a vector dose of 1.0 x 1012 VG/mouse. The mice 
were killed three weeks post injection and tissues were collected and analyzed via LacZ 
enzymatic activity (Fig. 2). HH67.2 had significantly higher LacZ activity in the heart (1.1 x 105 
± 3.8 x 104 U/ µg protein vs 2.2 x 104 ± 2.0 x 104 U/ µg protein, **p<0.005) and liver (716.4 ± 
51.9 U/ µg protein vs 245.8 ± 95.0 U/ µg protein, **p<0.005), while the tibialis anterior (TA) 
muscle trended higher when compared to the original HH67.  
 
Figure 2. Comparison of HH67 vs HH67.2 encoding LacZ reporter and CMV promoter 
by systematic delivery into adult C57BL/6 mice. The mice were sacrificed 3 weeks later 
for analysis of LacZ activity in samples from the tibialis anterior (TA) muscle, heart, 
and liver (** indicated p<0.005 by pair t-tests, n=3).  
 
 With the significant increase in heart transgene expression observed in HH67.2, we 
decided to next compare to it to the gold standard AAV9. Again, HH67.2 and AAV9 with the 
LacZ-CMV vector was systemically injected via tail vein in adult C57BL/6 mice at the same 
   
dose of 1.0 x 1012 VG/mouse. After 3 weeks post-injection, the mice were killed and tissues were 
collected (Fig. 3). Interestingly, analysis revealed HH67.2 had higher LacZ activity in the TA 
muscle (2.0 x 105 ± 6.5 x 104 U/ µg protein vs 5.6 x 104 ± 2.0 x 104 U/ µg protein, **p<0.005) 
and equivalent expression in heart using the CMV-LacZ reporter. Additionally, there was a 
significant decrease in liver transgene expression (1.3 x 104 ± 3.0 x 102 U/ µg protein vs 3.7 x 
104 ± 1.4 x 104 U/ µg protein, **p<0.005), suggesting HH67.2 has increased specificity and 
decreased ectopic expression compared to AAV9.  
 
Figure 3. Comparison of AAV9 vs HH67.2 for tissue specific transgene expression. Both 
were encoded with LacZ reporter and CMV promoter and systematically delivered into 
adult C57BL/6 mice. The mice were sacrificed 3 weeks later for analysis of LacZ activity 
in samples from the tibialis anterior (TA) muscle, heart, and liver (** indicated p<0.005 
by pair t-tests, n=5). 
 
 In order to confirm these findings, quantitative real-time PCR analysis was performed to 
measure AAV vector copy numbers from collected tissues (Fig. 4A). Vector DNA copy numbers 
were increased in HH67.2 TA muscle (2.84 ± 0.25 VC/cell vs 1.85 ± 0.37 vector copy (VC)/cell 
for AAV9, ***p=0.0008) and heart (9.09 ± 2.5 VC/cell vs 5.22 ± 2.48 VC/cell for AAV9, 
*p=0.0353) but decreased in liver (** p<0.005). Quantitative real-time PCR can be a more 
sensitive measure than measuring LacZ enzymatic activity and was able to measure a statistically 
   
significant increase in vector copy numbers in HH67.2 heart expression vs. AAV9. Additionally, 
X-Gal staining of cryo-thin sections of the heart, liver, and muscle further supported our 
findings. These further studies confirmed the exciting findings of increased tropism and 
specificity of the HH67.2 vector compared to AAV9 vector.  
 
Figure 3. Confirmation of tissue specific transgene expression for HH67.2 and wild-type 
AAV9 vectors encoding LacZ reporter. Both vectors controlled by the CMV promoter 
were injected into the tail vein for systemic delivery to adult C57BL/6 mice at a dose of 1 
x 1012 VG/mouse. The mice were killed 3 weeks post-injection. (A) Vector DNA copy 
numbers in the tibialis anterior (TA) muscle, heart, and liver (* indicates p<0.05, ** 
p<0.005, and *** p<0.001 by pair t-tests, n=5). (B) Photographs of X-Gal staining of 
representative tissues.  
 
 Despite the promising results, we were concerned the reduced transgene expression in the 
liver could be falsely low due to the CMV promoter, which can become inactive and no longer 
promote gene transcription. In order to verify our findings, we decided to package HH67-LacZ, 
HH67.2-LacZ, and wild type AAV9-LacZ into the chicken β-lactin (CB) promoter gene, which 
will not be inactivated in the liver. All AAV vectors (HH67-CB-LacZ, HH67.2-CB-LacZ, and 
AAV9-CB-LacZ) were systemically delivered to 6-to-8 week old C57BL/6 adult mice by tail 
   
vein injection at a vector dose of 1.2 x 1012 VG/mouse. After 4 weeks post-injection, the mice 
were killed and tissues were collected and analyzed via LacZ enzymatic activity, X-Gal staining, 
and viral copy number. The LacZ transgene expression in TA muscle was significantly increased 
in HH67.2-CB (2.5 x 105 ± 6.5 x 104 U/ µg protein) compared to AAV9-CB (7.2 x 104 ± 8.2 x 
103; **p<0.005) and HH67-CB (1.2 x 105 ± 7.4 x 104); however, we saw no significant 
difference in LacZ expression in heart or liver between the 3 vectors (Fig. 5A).  
 Next, we looked at the X-Gal staining for comparison of the 3 vectors using CB 
promoter to visually confirm enzymatic findings. The pancreas tissue was included to rule out 
non-specific transgene expression in other tissues besides the liver. The X-Gal staining 
reinforced previous findings and showed HH67.2-CB’s low non-specific transgene expression in 
liver and pancreas, while maintaining high muscle specificity (Fig. 5B).  
 Finally, vector copy number was evaluated via quantitative real-time PCR in order to 
evaluate for more subtle differences that were not able to be detected by the LacZ enzymatic 
activity or X-Gal staining. We found that HH67.2-CB maintained its tissue specific infectivity 
shown by the 3.5-fold increase in vector copies in the TA muscle (4.50 ± 2.07 VG/cell HH67.2 
vs 1.15 ± 0.197 VG/cell AAV9; *p<0.05) and heart compared to AAV9-CB (Fig. 5C). 
Interestingly, we were able to detect an 11-fold decreased in vector copy numbers in both 
HH67.2-CB and HH67-CB compared to AAV9-CB (HH67.2-CB 11.8 ± 2.5 VC/cell vs 126.8 ± 
39.6 VC/cell for AAV9-CB vs HH67-CB 16.8 ± 7.3 VC/cell, ***p <0.0001) suggesting liver de-
targeting had occurred.  
   
  
 
Figure 5. Comparison of AAV9, HH67, and HH67.2 encoding LacZ reporter and CB 
promoter by systematic delivery into adult C57BL/6 mice at a dose of 1.2 x 1012 
VG/mouse. The mice were killed 4 weeks post-injection. (A) Quantitation of LacZ 
expression by β-galactosidase activity assay (** p<0.005 by 1-way ANOVA, n=4). (B) 
Photographs of X-Gal staining of representative tissues. (C) Vector DNA copy numbers 
in the tibialis anterior (TA) muscle, heart, and liver (* indicates p<0.05, and *** p<0.001 
by 1-way ANOVA, n=4). 
 
   
Discussion:  
Therapeutic gene transfer to most of the striated muscle cells is necessary to achieve 
desirable effects in muscular dystrophy gene therapy. Due to the muscles’ wide-spread manner 
and high demand, AAV vector doses must be high to achieve systemic delivery and cross the 
tight endothelial barrier within the muscle14. The tyrosine-to-phenylalanine mutation has 
previously6 been shown to overcome intracellular trafficking, one of the rate limiting steps in 
AAV infection. By two key site mutations, Y445F and Y731F, we designed a stealthier AAV 
capsid HH67.2, which is theorized to be able to escape degradation by avoiding surface tyrosine 
phosphorylation and ubiquitination. We were able to show increased muscle specificity by up to 
3.5-fold compared to AAV9 and 11-fold decreased off target expression in the liver in HH67.2. 
Our results suggest that HH67.2 is a novel AAV vector with enhanced muscle specificity and 
infectivity compared to AAV9 and could be a promising vehicle to deliver therapeutic genes to 
skeletal muscle or heart without ectopic gene expression. 
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